

---

**Name of the Issue: Go Digit General Insurance Limited**


---

**1 Type of Issue** Initial Public Offer

**2 Issue Size (Rs. Mn)** 26146.46\*

*\*Source: Prospectus dated May 17, 2024*

**3 Grade of issue along with name of the rating agency**

**Name** NA

**Grade** NA

**4 Subscription Level (Number of times)** 10.03\*

*\*The above figure is after removing multiple or duplicate Bids*

*\*Source: Final post issue report dated May 27, 2024*

**5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges**

Particulars	%
-------------	---

(i) On Allotment**	19.09%
--------------------	--------

(ii) at the end of the 1st Quarter immediately after the listing of the issue (June 30, 2024) *	21.32%
---	--------

(iii) at the end of 1st FY (March 31, 2025)*	Not Available
--	---------------

(iv) at the end of 2nd FY (March 31, 2026) *	Not Available
--	---------------

(v) at the end of 3rd FY (March 31, 2027) *	Not Available
---	---------------

*\*\*Reporting with the BSE. Represents holding of Institutions category*

*\* QIB Holding not disclosed as reporting for relevant period has not been completed.*

**6 Financials of the issuer**

Parameters	1st FY (March 31,2025)*	2nd FY (March 31,2026)*	3rd FY (March 31,2027)*
Income from operations	Not Available	Not Available	Not Available
Net Profit/(Loss) for the period	Not Available	Not Available	Not Available
Paid-up equity share capital	Not Available	Not Available	Not Available
Reserves excluding revaluation reserves	Not Available	Not Available	Not Available

*\* Financials not available as reporting for the relevant years has not been completed.*

## 7 Trading Status

The equity shares of Mankind Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)*	Not Available
(ii) at the end of 2nd FY (March 31, 2026)*	Not Available
(iii) at the end of 3rd FY (March 31, 2027)*	Not Available

\* Trading status not disclosed as the relevant fiscal years have not been completed.

## 8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2025)*	Not Available	Not Applicable
(ii) at the end of 2nd FY (March 31, 2026)*	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	Not Available

\* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

## 9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

## 10 Status of utilization of issue proceeds

Particulars	In Million	
	Amount proposed to be financed from Net Proceeds	Estimated Utilisation of Net Proceeds in Fiscal 2025
Investments to maintain solvency ratio	10647.00	10647.00
General Corporate Purposes	-	-
<b>Total Proceeds</b>	<b>10647.00</b>	<b>10647.00</b>

Source: Prospectus dated May 17, 2024

(ii) Actual implementation

Particulars	Amount proposed to be financed from Net Proceeds	Actual Utilisation of Net Proceeds	Unutilised Net Proceeds
Investments to maintain solvency ratio	10647.00	0.00	10647.00
General corporate purposes	-	-	-
<b>Total Proceeds</b>	<b>10647.00</b>	<b>0.00</b>	<b>10647.00</b>

(iii) Reasons for delay in implementation, if any Not applicable

**11 Comments of monitoring agency, if applicable**

(i) Comments on use of funds

(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document

(iii) Any other reservations expressed by the monitoring agency about the end use of funds

There has been no deviation. The nil statement under regulation 32 of SEBI Listing Regulation in this regard has been reviewed by Audit Committee at its meeting held on 25th July 2024.  
Not applicable  
Not applicable

**12 Pricing Data**

Designated Stock Exchange	NSE		
Issue Price (Rs.)	272.00		
Listing Date	23-May-24	22-Jun-24	21-Aug-24

Price parameters	At close of listing day- 23-05-2024	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March,2025) <sup>(1)</sup>		
				Closing price	High	Low
Market Price	306.00	334.10	358.25	Not Available	Not Available	Not Available
Nifty 50*	22,967.65	23,501.10	24,770.20	Not Available	Not Available	Not Available

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March,2026) <sup>(1)</sup>			As at the end of the 3rd FY after the listing of the issue (31st March,2027) <sup>(1)</sup>		
	Closing price	High	Low	Closing price	High	Low
Market Price	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Nifty 50*	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

\* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

(2) Closing prices have been considered. In case of the date falling on holiday, previous working day has been considered

**13 Basis for Issue Price**

Accounting ratio	Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2025)**	At the end of 1st FY (March 31,2026)**	At the end of 1st FY (March 31,2027)**	
<b>EPS (Diluted)</b>	<b>Company</b>					
	<i>Consolidated</i>	10	0.40	Not Available	Not Available	Not Available
	<b>Peer Group:</b>					
	<i>New India Assurance Company Limited</i>	5	6.36			
	<i>Star Health and Allied Insurance Company Limited</i>	10	10.41	Not Available	Not Available	Not Available
	<i>ICICI Lombard General Insurance Company Ltd</i>	10	35.16	Not Available	Not Available	Not Available
	<b>Industry Avg</b>		17.31	Not Available	Not Available	Not Available
<b>P/E</b>	<b>Company</b>					
	<i>Consolidated</i>		NA	Not Available	Not Available	Not Available
	<b>Peer Group:</b>					
	<i>New India Assurance Company Limited</i>		38.47	Not Available	Not Available	Not Available
	<i>Star Health and Allied Insurance Company Limited</i>		53.79	Not Available	Not Available	Not Available
	<i>ICICI Lombard General Insurance Company Ltd</i>		48.14	Not Available	Not Available	Not Available
	<b>Industry Avg</b>		46.80	Not Available	Not Available	Not Available
<b>RoNW</b>	<b>Company</b>					
	<i>Consolidated</i>		1.53%	Not Available	Not Available	Not Available
	<b>Peer Group:</b>					
	<i>New India Assurance Company Limited</i>		5.13%	Not Available	Not Available	Not Available
	<i>Star Health and Allied Insurance Company Limited</i>		11.39%	Not Available	Not Available	Not Available
	<i>ICICI Lombard General Insurance Company Ltd</i>		16.64%	Not Available	Not Available	Not Available
	<b>Industry Avg</b>		11.05%	Not Available	Not Available	Not Available

		<b>Company</b>				
<b>NAV per share</b>	<i>Consolidated</i>	26.61	Not Available	Not Available	Not Available	
	<b>Peer Group:</b>					
	<i>New India Assurance Company Limited</i>	125.64	Not Available	Not Available	Not Available	
	<i>Star Health and Allied Insurance Company Limited</i>	93.35	Not Available	Not Available	Not Available	
	<i>ICICI Lombard General Insurance Company Ltd</i>	211.60	Not Available	Not Available	Not Available	
	<b>Industry Avg</b>	143.53	Not Available	Not Available	Not Available	

Notes

\* Sourced from Prospectus dated May 17, 2024.

\*\*Not available as the relevant fiscal years have not been completed / information not disclosed

#### 14 Any other material information

<b>Particulars</b>	<b>Date</b>	<b>Remarks</b>
For further updates and information, please refer stock exchange websites i.e. <a href="http://www.bseindia.com">www.bseindia.com</a> and <a href="http://www.nseindia.com">www.nseindia.com</a>		
Source: Stock Exchange filings		